Clicky

Orchard Therapeutics plc(ORTX)

Description: Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Orchard’s advanced portfolio of autologous ex vivo gene therapies targets serious and life-threatening rare diseases, initially primary immune deficiencies, neurometabolic disorders and hemoglobinopathies.


Keywords: Biotechnology Biopharmaceutical Rare Diseases Metabolic Disorders Immunodeficiency Hemoglobin Hemoglobinopathies Primary Immunodeficiency Hemoglobinopathy

Home Page: www.orchard-tx.com

ORTX Technical Analysis

108 Cannon Street
London, EC4N 6EU
United Kingdom
Phone: 44 20 3 808 8286


Officers

Name Title
Dr. Bobby Gaspar M.D., Ph.D. CEO, Member of Scientific Advisory Board & Exec. Director
Mr. Frank E. Thomas Pres & COO
Dr. Nicoletta Loggia Ph.D. Chief Technical Officer
Dr. Fulvio Mavilio Ph.D. Chief Scientific Officer
Ms. Renee T. Leck Director of Investor Relations
Benjamin Navon Director of Corp. Communications
Mr. John Cerio Chief Human Resource Officer
Mr. Robin Kenselaar Sr. VP & GM of EMEA Commercial Operations
Mr. Braden Parker Chief Commercial Officer
Dr. Leslie Meltzer Ph.D. Chief Medical Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4506
Price-to-Sales TTM: 3.4512
IPO Date: 2018-10-31
Fiscal Year End: December
Full Time Employees: 259
Back to stocks